| Recruiting | Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metast NCT04119024 | Anusha Kalbasi | Phase 1 |
| Unknown | Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment NCT06151847 | University of Kansas Medical Center | Phase 2 |
| Active Not Recruiting | Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients NCT05176470 | Richard Wu | Phase 1 |
| Recruiting | Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positiv NCT05098210 | Fred Hutchinson Cancer Center | Phase 1 |
| Recruiting | Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors NCT07259304 | University of Southern California | — |
| Active Not Recruiting | A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment i NCT04708418 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or NCT04940299 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement NCT04221438 | ECOG-ACRIN Cancer Research Group | Phase 2 |
| Recruiting | IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors NCT05039801 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma NCT04527549 | ECOG-ACRIN Cancer Research Group | Phase 2 |
| Terminated | Bone Loss in Melanoma Survivors Receiving Immunotherapy NCT04516122 | M.D. Anderson Cancer Center | — |
| Terminated | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progress NCT04902040 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer NCT03819296 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV NCT04462406 | ECOG-ACRIN Cancer Research Group | Phase 2 |
| Terminated | Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype NCT04375527 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Terminated | Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage III NCT04310397 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immuno NCT04990726 | M.D. Anderson Cancer Center | — |
| Active Not Recruiting | Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or M NCT03816332 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma NCT03727789 | Roswell Park Cancer Institute | Phase 1 |
| Terminated | Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma NCT03865212 | Mayo Clinic | Phase 1 |
| Completed | Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer NCT04067960 | Mayo Clinic | EARLY_Phase 1 |
| Active Not Recruiting | Young Melanoma Family Facebook Intervention or Healthy Lifestyle Facebook Intervention in Improving Skin Exami NCT03677739 | Rutgers, The State University of New Jersey | N/A |
| Active Not Recruiting | VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma NCT03769155 | Emory University | Phase 1 |
| Active Not Recruiting | Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma NCT03554083 | Mayo Clinic | Phase 2 |
| Active Not Recruiting | Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY NCT02650986 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Terminated | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherap NCT02419495 | M.D. Anderson Cancer Center | Phase 1 |